Nancy A. Melville A case of false-positive alcohol toxicology tests believed to be linked to treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors raises concern that the widely used diabetes drugs could feasibly be a cause of innumerable false-positive test results — with a lack of proper refrigeration of the samples being a key culprit. The...
Tag: <span>SGLT2 inhibitors</span>
Post
SGLT2 Inhibitors: Cause of False-Positive Test Results?
Nancy A. Melville A case of false-positive alcohol toxicology tests believed to be linked to treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors raises concern that the widely used diabetes drugs could feasibly be a cause of innumerable false-positive test results — with a lack of proper refrigeration of the samples being a key culprit. The...
Post
Which Patients With Type 2 Diabetes Need SGLT2 Inhibitors?
Agents that form the sodium-glucose cotransporter 2 inhibitor class – including canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) – have show remarkably consistent cardiovascular efficacy and safety for treating patients with heart failure, chronic kidney disease, and higher-risk patients with type 2 diabetes. But despite an essential role now established for drugs in the SGLT2...
Post
SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 inhibitors
by Brigham and Women’s Hospital Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way. Since that time, evidence in favor of the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors has been mounting, with studies showing better blood glucose control, cardiovascular benefits, weight loss...
Post
Gout incidence down with SGLT2 inhibitors in type 2 diabetes
Adults with type 2 diabetes newly prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study published online Jan. 14 in the Annals of Internal Medicine. Michael Fralick, M.D., Ph.D., from Brigham and Women’s Hospital and Harvard Medical School in...
Post
New class of type 2 diabetes drug associated with rare, life-threatening outcome
A new class of drugs, known as SGLT2 inhibitors, is increasingly being prescribed for the treatment of type 2 diabetes, but may increase the risk of rare but serious complication known as diabetic ketoacidosis. In a new study published in the New England Journal of Medicine, investigators from Brigham and Women’s Hospital quantify that risk, finding...